• 1
    Mitsuya H., Broder S. (1987) Strategies for antiviral therapy in AIDS. Nature;325:773778.
  • 2
    De Clercq E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res;38:153179.
  • 3
    Stevens M., De Clercq E., Balzarini J. (2006) The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Chem Rev;26:595625.
  • 4
    Meadows D.C., Gervay H.J. (2006) Current developments in HIV chemotherapy. Chem Med Chem;1:1629.
  • 5
    Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science;267:988993.
  • 6
    Barbaro G., Scozzafava A., Mastrolorenzo A., Supuran C.T. (2005) Highly active antiretroviral therapy: current state of the art new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des;11:18051843.
  • 7
    Koup R.A., Merluzzi V.J., Hargrave K.D., Adams J., Grozinger K., Eckner R.J., Sullivan J.L. (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis;163:966970.
  • 8
    Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R. et al. (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother;39:26022605.
  • 9
    Freimuth W.W. (1996) Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Med Bio;394:279289.
  • 10
    Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van G.J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., Janssen P.A.J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature;343:470474.
  • 11
    Balzarini J., Pelemans H., Aquaro S., Perno C.F., Witvrouw M., Schols D., De Clercq E., Karlsson A. (1996) Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol Pharmacol;50:394401.
  • 12
    Goldman M.E., Nunberg J.H., O’Brien J.A., Quintero J.C., Schleif W.A., Freund K.F., Gaul S.L., Saari W.S., Wai J.S., Hoffman J.M., Anderson P.S., Hupe D.J., Emini E.A., Stern A.M. (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci USA;88:68636867.
  • 13
    Patel M., Ko S.S., McHugh R.J.J., Markwalder J.A., Srivastava A.S., Cordova B.C., Klabe R.M., Erickson-Viitanen S., Trainor G.L., Seitz S.P. (1999) Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett;9:28052810.
  • 14
    De Clercq E. (1999) Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco;54:2645.
  • 15
    Ilina T., Parniak M.A. (2008) Inhibitors of HIV-I reverse transcriptase. Adv Pharmacol;56:121167.
  • 16
    Wang Z., Wu B., Kuhen K.L., Bursulaya B., Nguyen T.N., Nguyen D.G., He Y. (2006) Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett;16:41744177.
  • 17
    Muraglia E., Kinzel O.D., Laufer R., Miller M.D., Moyer G., Munshi V., Orvieto F., Palumbi M.C., Pescatore G., Rowley M., Williams P.D., Summa V. (2006) Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg Med Chem Lett;16:27482752.
  • 18
    Zhan P., Liu X., Cao Y., Wang Y., Pannecouque C., De Clercq E. (2008) 123-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett;18:53685371.
  • 19
    Zhang Z., Xu W., Koh Y.H., Shim J.H., Girardet J.L., Yeh L.T., Hamatake R.K., Hong Z. (2007) A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother;51:429437.
  • 20
    Hu R., Barbault F., Delamar M., Zhang R. (2009) Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem;17:24002409.
  • 21
    Yong S.R., Ung A.T., Pyne S.G., Skelton B.W., White A.H. (2007) Synthesis of novel 3′-spirocyclic-oxindole derivatives and assessment of their cytostatic activities. Tetrahedron;63:55795586.
  • 22
    Rodinovskaya L.A., Shestopalov A.M., Gromova A.V., Shestopalov A.A. (2008) One-pot synthesis of diverse 4-di(tri)fluoromethyl-3-cyanopyridine-2(1H)-thiones and their utilities in the cascade synthesis of annulated heterocycles. J Comb Chem;10:313322.
  • 23
    Liu K., Lu H., Hou L., Qi Z., Teixeira C., Barbault F., Fan B.T., Liu S., Jiang S., Xie L. (2008) Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem;51:78437854.
  • 24
    Kanamoto T., Kashiwada Y., Kanbara K., Gotoh K., Yoshimori M., Goto T., Sano K., Nakashima H. (2001) Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother;45:12251230.
  • 25
    Silvestri R., Artico M., De Martino G., Ragno Ri., Massa S., Loddo R., Murgioni C., Loi A.G., La Colla P., Pani A. (2002) Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. J Med Chem;45:15671576.
  • 26
    De Martino G., La Regina G., Di Pasquali A., Ragno R., Bergamini A., Ciaprini C., Sinistro A., Maga G., Crespan E., Artico M., Silvestri R. (2005) Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem;48:43784388.
  • 27
    Shrestha A.R., Ali H.I., Ashida N., Nagamatsu T. (2008) Antitumor studies, part 5: synthesis antitumor activity and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins. Bioorg Med Chem;16:91619170.
  • 28
    Kovac A., Konc J., Vehar B., Bostock J.M., Chopra I., Janezic D., Gobec S. (2008) Discovery of new inhibitors of d-Alanine: d-Alanine ligase by structure-based virtual screening. J Med Chem;51:74427448.
  • 29
    Ding J., Das K., Tantillo C., Zhang W., Clark A.D.J., Jessen S., Lu X. et al. (1995) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2.8 Å resolution. Structure;3:365379.
  • 30
    Ren J., Diprose J., Warren J., Esnouf R.M., Bird L.E., Ikemizu S., Slater M., Milton J., Balzarini J., Stuart D.I., Stammers D.K. (2000) Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases: structural and biochemical analyses. J Biol Chem;275:56335639.
  • 31
    Schafer W., Friebe W.G., Leinert H., Mertens A., Poll T., Von Der Saal W., Zilch H., Nuber B., Ziegler M.L. (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. J Med Chem;36:726732.
  • 32
    Jonckheere H., Anne J., De Clercq E. (2000) The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med Res Rev;20:129154.
  • 33
    Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., Bozzette S.A. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS;18:13931401.
  • 34
    Paul M.K., Mukhopadhyay A.K. (2004) Tyrosine kinase-role and significance in cancer. Int J Med Sci;1:101115.